Table: Towa Pharmaceutical -2022/23 parent results
May 15 (Reuters)-
Towa Pharmaceutical Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2023 Mar 31, 2022 Mar 31, 2024 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 124.00 123.30
(+0.6 pct) (+6.9 pct)
Operating 9.31 18.74
(-50.3 pct) (-6.0 pct)
Recurring 8.54 22.49
(-62.0 pct) (+20.7 pct)
Net 6.33 16.32
(-61.2 pct) (+19.5 pct)
EPS 128.60 yen 331.57 yen
EPS Diluted 324.22 yen
Ann Div 60.00 yen 60.00 yen 60.00 yen
-Q2 Div 30.00 yen 27.00 yen 30.00 yen
-Q4 Div 30.00 yen 33.00 yen 30.00 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results